Ewa Wojcik

Ewa Wojcik

Auto-generated profile, based on publicly available information

Ewa Wojcik

Department of Clinical Biochemistry, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow, Poland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2006 in Oncology
Verified
Journal Article
Closed access
Joanna KamińskaJoanna Kamińska
Joanna Kamińska
MKMaria Kowalska
Maria Kowalska
BKBeata Kotowicz
Beata Kotowicz
MFMalgorzata Fuksiewicz
Malgorzata Fuksiewicz
MGMaciej Glogowski
Maciej Glogowski
JSJan Steffen
Jan Steffen
Objectives: Cytokines are potential new serum markers, especially desirable for malignancies with poor prognosis like non-small cell lung cancer (NSCLC). Methods: Cytokines, tumor necrosis factor α (TNFα), interleukin (IL)-6 and IL-8, soluble TNF (sTNF) RI, sTNF RII, soluble IL-2 receptor-α, IL-1 receptor antagonist (IL-1ra), IL-10, vascular endothelial growth factor, basic fibroblast growth factor, and macrophage (M-CSF) and granulocyte colony-stimulating factor, as well as tumor markers – carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and CYFRA 21.1 – were assessed in the sera of 103 untreated NSCLC patients, and these cytokines and tumor markers were refered to clinical parameters of the disease and to the overall survival of patients evaluated during a 6-year follow-up. Results: Most of the factors analyzed were found to be elevated in the sera of NSCLC patients, and increases in IL-6, IL-8 and sTNF RI were noted in the greatest proportion of stage I patients. Most cytokine/cytokine receptor levels revealed higher sensitivity than the standard tumor markers; IL-6 and IL-1ra levels were significantly different in patients with squamous cell versus adenocarcinoma; IL-6 and IL-10 were related to the tumor size, while IL-6 and M-CSF levels significantly increased with disease progression. A significant prognostic value of pretreatment serum M-CSF and CEA levels in NSCLC patients has been shown, but only M-CSF proved to be an independent prognostic factor. Conclusions: Increased pretreatment serum M-CSF level is a significant independent predictor of poor survival in patients with NSCLC.

1 November 2017 in Lung Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
EWEwa Wojcik
Ewa Wojcik
JKJan Kanty Kulpa
Jan Kanty Kulpa
Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morphological, biological and clinical features justify the distinction of small-cell carcinoma with respect to the other histological types of lung cancer. The predominant neuroendocrine phenotype is critical for the selection of biomarkers used in diagnostics, monitoring and evaluation of treatment response; early onset relapses in patients with small-cell lung cancer (SCLC) and the evaluation of their prognosis. Although for a long time the neuron-specific enolase (NSE) was considered to be the marker of choice for this tumor, it is now increasingly important to pay attention to concentrations of pro-gastrin-releasing peptide (ProGRP). The results of this marker have been implicated in the differential diagnosis of non-small lung cancer and SCLC, chemotherapy and radiotherapy monitoring as well as evaluation of treatment response. The subject of this series of studies is to determine the usefulness of ProGRP in the evaluation of patients’ prognosis and its predictive value. The current aim for the optimization of the effectiveness of biochemical diagnostics of SCLC is recommended by complementary ProGRP and NSE studies. The present work is a summary of the latest reports regarding diagnostic utility of these markers in SCLC.

27 November 2008
Verified
Journal Article
Closed access
EWEwa Wojcik
Ewa Wojcik
JKJan Kulpa
Jan Kulpa
BSBeata Sas-Korczyńska
Beata Sas-Korczyńska
SKStanisław Korzeniowski
Stanisław Korzeniowski
JJJerzy Jakubowicz
Jerzy Jakubowicz

21 May 2010 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
BSBeata Sas-Korczyńska
Beata Sas-Korczyńska
SKStanisław Korzeniowski
Stanisław Korzeniowski
EWEwa Wójcik
Ewa Wójcik

1 May 2010
Verified
Journal Article
Closed access
EWEwa Wojcik
Ewa Wojcik
JJJerzy Jakubowicz
Jerzy Jakubowicz
PSPiotr Skotnicki
Piotr Skotnicki
BSBeata Sas-Korczyńska
Beata Sas-Korczyńska
JKJan Kulpa
Jan Kulpa

1 January 2016 in Clinical Laboratory
Verified
Journal Article
Closed access
EWEwa Wojcik
Ewa Wojcik
JTJadwiga Tarapacz
Jadwiga Tarapacz
URUrszula Rychlik
Urszula Rychlik
ZSZofia Stasik
Zofia Stasik
BSBeata Sas-Korczyńska
Beata Sas-Korczyńska
JKJan Kulpa
Jan Kulpa
The aim of the present study was to compare the diagnostic utility of HE4 with NSE, ProGRP, CYFRA 21-1, CEA, and CA 125 and evaluate their prognostic value in patients with small-cell lung cancer (SCLC). HE4, ProGRP, NSE, CYFRA 21-1, CEA, and CA 125 assays were performed in 63 patients with smallcell lung cancer (limited disease (LD) - 41, extensive disease (ED) - 22) and in 66 individuals of the reference group. Area under the ROC curves for HE4, ProGRP, NSE, CA 125, CYFRA 21-1, and CEA were 0.884, 0.923, 0.826, 0.796, 0.739, and 0.704, respectively. The tumor marker serum concentrations were associated with tumor stage (HE4, ProGRP, NSE, CYFRA 21-1, CEA), and disease progression occurred within one year (HE4, ProGRP, NSE, CYFRA 21-1). The tumor advancement, performance status, gender and tumor markers, except CEA and CA 125, were significantly associated with survival. Independent, unfavourable prognostic factors included extensive disease (HR 4.14, p < 0.0001) and NSE concentration above 35 g/l (HR 2.62, p = 0.0009). Diagnostic utility of HE4 was similar to that of NSE and ProGRP. Complementary to NSE, determination of HE4 seems to be helpful in evaluation of SCLC patients' prognosis.